Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis

Next Previous
Search
Trial Profile

An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netakimab (Primary)
  • Indications Plaque psoriasis; Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms PATERA
  • Sponsors Biocad

    • Most Recent Events

    • 05 Jun 2021 Results of subanalysis; assessing ACR (American College of Rheumatology) 20/50/70 response rate in PsA patients with/without the axial disease, presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 05 Jun 2021 Results of subanalysis assessing effect of Netakimab on domains of EQ-5D-5L in patients with inflammatory back pain and without at baseline presented at the 22nd Annual Congress of the European League Against Rheumatism
    • 21 Jul 2020 Planned End Date changed from 31 Jan 2021 to 1 Nov 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top